RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Risk of cardiovascular, gastrointestinal, and renal adverse events associated with diclofenac immediate and extended release drug products
An observational study using US claims data
Mladsi, D., Goyal, R., Cryer, B., Hopkins, WE., Brater, CD., Korsnes, J., Candrilli, S., Castellsague, J., & Varas-Lorenzo, C. (2015). Risk of cardiovascular, gastrointestinal, and renal adverse events associated with diclofenac immediate and extended release drug products: An observational study using US claims data. Value in Health, 18(3), A292. https://doi.org/10.1016/j.jval.2015.03.1701
Safety studies have shown that risks associated with use of non-steroidal anti-inflammatory drugs (NSAIDs) are related to dose and release form; however, there is little US evidence. This study assessed the relationships between diclofenac dose and release form on gastrointestinal (GI), cardiovascular (CV), and renal events using US health care claims.